Core Viewpoint - NRx Pharmaceuticals and its subsidiary HOPE Therapeutics will participate in an H.C. Wainwright fireside discussion on April 22, 2025, focusing on their developments in the biopharmaceutical and interventional psychiatry sectors [1][2][8]. Company Overview - NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics for central nervous system disorders, including suicidal bipolar depression, chronic pain, and PTSD [4]. - The company is advancing NRX-101, which has received FDA designation as a Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain, with plans to file a New Drug Application for Accelerated Approval [4]. - NRx has also initiated the filing of a New Drug Application for NRX-100 (IV ketamine) for treating suicidal depression, supported by clinical trial results and data from French health authorities [5]. HOPE Therapeutics Overview - HOPE Therapeutics is a development stage healthcare delivery company aiming to create a network of interventional psychiatry clinics offering ketamine and transcranial magnetic stimulation (TMS) therapies for patients with suicidal depression [6]. - The company plans to integrate a digital therapeutic platform to enhance the clinical benefits of NMDA-targeted drug therapies [6].

Investment to support initiation of HOPE's network of clinics to treat suicidal depression and PTSD with ketamine, TMS and other modalities MIAMI, April 3, 2025 /PRNewswire/ -- HOPE Therapeutics, Inc., ("HOPE," the "Company"), an interventional psychiatry network wholly owned by NRx Pharmaceuticals, Inc. ("NRx") (Nasdaq:NRXP), today announced signing of a term sheet with a global medical device manufacturer, as anticipated in the Company's recently filed annual report. The investor shares HOPE's vision of ...

MIAMI, March 31, 2025 /PRNewswire/ -- HOPE Therapeutics, Inc., ("HOPE," the "Company"), an interventional psychiatry network wholly owned by NRx Pharmaceuticals, Inc. ("NRx") (Nasdaq: NRXP), today announced signing of a definitive Agreement to acquire Dura Medical (Dura), per the previously announced non-binding Letter of Intent. Dura, together with the previously announced Neurospa network, are anticipated to provide a comprehensive service offering to patients on Florida's west coast. Dura is revenue gene ...

Shares of NRx Pharmaceuticals, Inc. (NRXP) have been struggling lately and have lost 5.1% over the past week. However, a hammer chart pattern was formed in its last trading session, which could mean that the stock found support with bulls being able to counteract the bears. So, it could witness a trend reversal down the road.The formation of a hammer pattern is considered a technical indication of nearing a bottom with likely subsiding of selling pressure. But this is not the only factor that makes a bullis ...

Neurospa currently operates six interventional psychiatry clinics on Florida's Gulf Coast HOPE to acquire majority interest in Neurospa for a combination of cash and equity Neurospa clinics deliver a full range of interventional psychiatry services, including Ketamine, Spravato® and Transcranial Magnetic Stimulation (TMS) to patients with severe depression and related conditions Acquisition to be accretive to HOPE revenue projections for 2025 MIAMI, March 24, 2025 /PRNewswire/ -- HOPE Therapeutics, Inc., ( ...

Financial Performance - NRx Pharmaceuticals reported a reduction in operational loss by approximately $2.0 million to $2.4 million for Q4 2024, a nearly 45% improvement compared to Q4 2023[23]. - For the year ended December 31, 2024, the company reduced its loss from operations by approximately $9.3 million, or 33.5%, to $18.5 million from $27.8 million in 2023[24]. - NRx Pharmaceuticals has completed financing agreements totaling $10.9 million in 2024 and $8.5 million in January 2025 to support ongoing operations and clinic expansions[20][25]. - Management forecasts potential profitability on a forward-looking run-rate basis by year-end 2025, although no assurances can be given[3]. Research and Development - Research and development expenses decreased by approximately $1.5 million to $1.0 million in Q4 2024, down from $2.5 million in Q4 2023, primarily due to the conclusion of the phase 2b/3 study for NRX-101[23]. - NRx has initiated a New Drug Application filing for NRX-100 (IV ketamine) for the treatment of suicidal depression[30]. - NRx was awarded Fast Track Designation by the US FDA for the development of ketamine (NRX-100) to treat patients with acute suicidality[30]. Product Development and Licensing - The anticipated PDUFA date for the NDA filing of NRX-100 is prior to December 31, 2025, targeting the $3 billion Suicidal Depression market in the US[6][7]. - The company has accepted non-binding terms for licensing NRX-100, which includes over $300 million in potential milestones plus tiered double-digit royalties based on net sales[3][7]. - NRx Pharmaceuticals plans to file an ANDA for preservative-free ketamine in Q2 2025, aiming to address all currently indicated human and veterinary applications[9]. Strategic Growth and Acquisitions - The company aims to acquire 15-20 psychiatry clinics in Florida by year-end 2025, with each clinic currently generating approximately $5 million in revenue[19][18]. - The company is negotiating terms with a strategic investor for capital to support further HOPE clinic acquisitions, enhancing its interventional psychiatry services[3][21]. - HOPE Therapeutics aims to develop a network of interventional psychiatry clinics offering ketamine TMS and other therapies for suicidal depression[31]. - HOPE Therapeutics is focused on acquiring providers for its national network and raising adequate capital for these acquisitions[32]. - The company intends to spin-off HOPE Therapeutics as part of its growth strategy[32]. Risks and Forward-Looking Statements - The company acknowledges risks and uncertainties that may affect future financial performance and operational results[32]. - Investors are encouraged to review the company's most recent Annual Report on Form 10-K for detailed risk factors[32]. - The company does not assume any obligation to update forward-looking statements unless required by law[32]. Management - Matthew Duffy serves as Chief Business Officer of NRx Pharmaceuticals and Co-Chief Executive Officer of HOPE Therapeutics[33].

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Q4 2024 Earnings Conference Call March 17, 2025 8:30 AM ET Company Participants Matthew Duffy - Chief Business Officer Jonathan Javitt - Founder, Chairman and Chief Scientist Michael Abrams - Chief Financial Officer Conference Call Participants Jason Kolbert - D. Boral Capital Thomas Shrader - BTIG Vernon Bernardino - H.C. Wainwright Ed Woo - Ascendiant Capital Operator Good morning, ladies and gentlemen, and welcome to the NRx Pharmaceuticals 4Q and Full Year 2024 Ea ...

Initiated filing of a New Drug Application ("NDA") to the FDA for NRX-100 (IV Ketamine) for the treatment of Suicidal Depression; planned filing of an NDA for Accelerated Approval under Breakthrough Designation and Priority Review of NRX-101 for the treatment of bipolar depression in people at risk of akathisia. Both have anticipated PDUFA dates prior to December 31, 2025 The Company has accepted non-binding potential terms from a commercial pharmaceutical company to license and distribute NRX-100, providi ...

Financing and Capital Structure - NRx Pharmaceuticals closed $10.87 million in debt capital financing in 2024 and an additional $8.5 million in January 2025, totaling $16.3 million from institutional investors[472]. - The Company secured $8.5 million in new financing subsequent to December 31, 2024, to support working capital requirements through the end of fiscal year 2025[498]. - The Company entered into a securities purchase agreement on January 27, 2025, for the sale of 1,215,278 shares at a purchase price of $2.88 per share, generating gross proceeds of approximately $3.5 million[499][500]. - The Company executed an agreement on August 12, 2024, to sell and issue $16.3 million of Notes and Warrants, with proceeds used to settle outstanding amounts owed and for working capital needs[532]. - The Company completed the February 2024 Public Offering with gross proceeds of approximately $1.7 million, selling shares at a public offering price of $3.00 each, while underwriters purchased at $2.76 per share[537]. - The February 2024 Private Placement raised approximately $1.0 million by issuing 270,000 shares at a price of $3.80 per share, representing a 26.7% premium to the public offering price[539]. - Financing activities provided $7.485 million in cash during 2024, primarily from the issuance of common stock and warrants, offset by $7.9 million in repayments of convertible notes[545]. Research and Development - The company initiated a New Drug Application (NDA) for NRX-101 in Q4 2024, with an anticipated FDA decision date by June 30, 2025[474]. - NRX-101 received Qualified Infectious Disease Product designation and Fast Track designation for treating Complicated Urinary Tract Infection[479]. - The company is developing HTX-100, a novel pH neutral formulation of ketamine, expected to begin clinical testing by 2026[477]. - For the year ended December 31, 2024, the company recorded $6.2 million in research and development expenses, a decrease of $7.2 million from $13.4 million in 2023, primarily due to the conclusion of the phase 2 study related to NRX-101[519]. - The Company has a contractual obligation to pay milestone payments of $0.3 million upon completion of phase 3 trials for NRX-101, along with ongoing royalties of 1% to 2.5% of gross sales[548]. Financial Performance - For the years ended December 31, 2024 and 2023, NRx Pharmaceuticals reported net losses of $25.1 million and $30.2 million, respectively[506]. - The company reported a net loss of $25.1 million for the year ended December 31, 2024, an improvement of $5.0 million from a net loss of $30.2 million in 2023[518]. - The net cash used in operating activities for the year ended December 31, 2024, was approximately $10.6 million, resulting from a net loss of $25.1 million[542]. - The Company reported a net cash decrease of $3.152 million for the year ended December 31, 2024, compared to a decrease of $15.459 million in 2023[542]. - The Company has generated no revenues and expects to continue incurring significant operating losses, relying on equity and/or debt financing to continue operations[527]. - The Company has no revenues and has suffered operating losses since inception, raising substantial doubt about its ability to continue as a going concern[569]. Assets and Liabilities - As of December 31, 2024, NRx Pharmaceuticals had an accumulated deficit of $278.3 million and a stockholders' deficit of $23.5 million[506]. - As of December 31, 2024, the Company reported total assets of $3.651 million, a decrease from $7.315 million in 2023, and total liabilities increased to $26.874 million from $19.048 million[542]. - The Company incurred a working capital deficit of $18.8 million as of December 31, 2024[506]. - The Company reported a working capital deficit as of December 31, 2024[569]. Compliance and Regulatory Matters - The Nasdaq Stock Market notified the Company on July 20, 2023, regarding non-compliance with the minimum market value of listed securities requirement of $50 million[510]. - The company received a written notification from Nasdaq on August 6, 2024, indicating non-compliance with the minimum market value of listed securities requirement of $35 million for 33 consecutive business days[512]. - The Company transferred its listing from the Nasdaq Global Market to the Nasdaq Capital Market on January 19, 2024, after receiving an exception to the Nasdaq Listing Rules[511]. Strategic Initiatives - A non-binding offer was accepted for licensing NRX-100, which includes potential milestones of $325 million and royalties ranging from 11% to 16% of sales[474]. - NRx is negotiating to acquire three precision psychiatry centers and six additional centers to expand its HOPE network[477]. - The company anticipates expanding its treatment offerings to include PTSD by year-end 2025, contingent on successful acquisitions[477]. - NRx engaged BTIG to identify additional clinic candidates to meet projected revenue targets by the end of 2025[477]. - The Company is negotiating with a publicly-traded entity for acquisition capital to support the expansion of HOPE, aiming to finance less than 50% of the proposed acquisition costs[504]. Operational Expenses - General and administrative expenses for the year ended December 31, 2024, were $13.5 million, down from $14.2 million in 2023, reflecting a decrease of $0.7 million[520]. - The total operating expenses for the year ended December 31, 2024, were $18.5 million, a reduction of $9.3 million compared to $27.8 million in 2023[518]. Other Financial Matters - The Company recorded a default penalty of $0.8 million for the year ended December 31, 2024, due to alleged default in connection with the Streeterville convertible note[523]. - The fair value of the convertible note was estimated using a Monte Carlo simulation model, which is complex and subjective[575][576]. - The valuation of the convertible note as of December 31, 2024, was identified as a critical audit matter[576]. - Management's estimate of the fair value of the convertible note was agreed upon after independent testing of data and assumptions[577].

- Conference call to take place at 8:30am ET -WILMINGTON, Del., March 12, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its fourth quarter and full year 2024 financial results before the market opens on Monday, March 17, 2025 via press release, which will be available on the Company's website at https://ir.nrxpharma.com/. The Company will host a conference call to discuss ...